Drug Trial Radar · NCT02741596
Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
Last checked: Nov 20, 2026Latest source record: Jun 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
212
Actual
Start
May 26, 2016
Primary completion
Oct 31, 2019
Study completion Oct 31, 2019
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Apr 18, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, long term safety and efficacy study to evaluate DX-2930 in preventing acute angioedema attacks in participants with Type I and Type II HAE.
Conditions
- Hereditary Angioedema (HAE)
Interventions
DX-2930Drug
Participants who rollover from the DX-2930-03 study will receive 300 milligram (mg) DX-2930 subcutaneous injection at Day 0 followed by second dose following the first HAE attack and then once in every 2 weeks until the end of the treatment period (up to 924 days). A wash-out period of a minimum of 10 days and a maximum of 18 days is required between subsequent administrations.
DX-2930Drug
Participants who were not participants in DX-2930-03 will receive 300 milligram (mg) DX-2930 subcutaneous injection once in every 2 weeks until the end of the treatment period (up to 924 days).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From start of the study up to follow-up (Day 952)
Locations
43 sites in 7 countries. Site status is shown where the registry gives one.
Clinical Research Center of Alabama
Birmingham, Alabama
Medical Research of Arizona
Scottsdale, Arizona
University of California San Diego
San Diego, California
AIRE Medical of Los Angeles
Santa Monica, California
Allergy & Asthma Clinical Research
Walnut Creek, California
IMMUNOe Research Centers
Centennial, Colorado
Asthma and Allergy Associates, PC
Colorado Springs, Colorado
University of South Florida
Tampa, Florida
University of Kansas Medical Center
Kansas City, Kansas
Institute Asthma and Allergy
Chevy Chase, Maryland
Massachusetts General Hospital
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Midwest Immunology Clinic
Plymouth, Minnesota
Washington University School of Medicine
St Louis, Missouri
Hudson-Essex Allergy, LLC
Belleville, New Jersey
Atlantic Research Center, LLC
Ocean City, New Jersey
Winthrop University Hospital
Mineola, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Clinical Research Center of Charlotte
Charlotte, North Carolina
Duke Asthma, Allergy, and Airway Center
Durham, North Carolina
Bernstein Clinical Research Center, LLC
Cincinnati, Ohio
Optimed Research, LTD.
Columbus, Ohio
Toledo Institute of Clinical REsearch
Toledo, Ohio
Penn State Hershey Medical Center
Hershey, Pennsylvania
Austin Regional Clinic
Austin, Texas
AARA Research Center
Dallas, Texas
Intermountain Clinical Research
Draper, Utah
Allergy Associates of Utah
Murray, Utah
Virginia Commonwealth University
Richmond, Virginia
Premier Clinical Research
Spokane, Washington
Medical College of Wisconsin, Childrens Hospital
Milwaukee, Wisconsin
University of Alberta Hospital
Edmonton, Alberta, Canada
Yang Medicine
Ottawa, Ontario, Canada
Gordon Sussman Clinical Research, Inc.
Toronto, Ontario, Canada
Clinique Spécialisée en Allergie de la Capitale
Québec, Quebec, Canada
Charité - Universitätsmedizin Berlin
Berlin, Germany
Universitätsklinikum Frankfurt
Frankfurt, Germany
Hautklinik der Universitätsmedizin Mainz
Mainz, Germany
HZRM Hamophilie Zentrum Rhein Main GmbH
Mörfelden-Walldorf, Germany
University of Milan Luigi Sacco Hospital
Milan, Italy
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.